Astrazeneca plc, of London, said the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the marketing authorization of Lynparza (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have complete or partial response to platinum-based chemotherapy.